Sector News

Sanofi signs autoimmune pact with Lead Pharma

February 18, 2015
Life sciences
Sanofi has linked up with Lead Pharma of the Netherlands to develop drugs for a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.
The pact will focus on therapies directed against the nuclear hormone receptors called ROR gamma (t) which drives the production of key pro-inflammatory proteins including interleukin-17A, IL-17F and the receptor for IL-23. Sanofi and Lead say they have a goal of identifying drug candidates and beginning human trials within three-four years.
Financial details were not disclosed but the Dutch biotech will receive an upfront payment and is eligible for the usual development, regulatory and commercial milestones, plus royalties. Christian Antoni, head of Sanofi’s immunology and inflammation R&D, said that “anti-ROR gamma (t) therapies represent a ground-breaking opportunity that we are eager and motivated to pursue”.
Meantime still no official announcement from Paris about Sanofi’s new chief executive but numerous news sources, notably Bloomberg, say Olivier Brandicourt, head of Bayer’s healthcare business could be crowned in the newt few days. The Frenchman has been one of the front-runners for the post since Chris Viehbacher was sacked in October.
By Kevin Grogan
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]